EX-10.2



 Exhibit 10.2 

EXECUTION VERSION 
  

 
  

STOCKHOLDERS’ AGREEMENT 

dated as of 
 December
23, 2014 
 by and among 

CONKWEST, INC., 

SORRENTO THERAPEUTICS, INC., 

CAMBRIDGE EQUITIES, LP 

and 
 THE PERSONS LISTED
ON SCHEDULE A HERETO 
  
  

 







 STOCKHOLDERS’ AGREEMENT 

This STOCKHOLDERS’ AGREEMENT (this “Agreement”), is entered into as of December 23, 2014, by and among Conkwest, Inc.,
Sorrento Therapeutics, Inc., Cambridge Equities, LP, and the persons listed on Schedule A hereto (collectively, the “Stockholders”). 

WHEREAS, Cambridge Equities, LP (“Cambridge”) is entering into a Subscription and Investment Agreement, dated of even date herewith
(the “Subscription Agreement”), with Conkwest, Inc. (the “Company”), pursuant to which Cambridge will acquire approximately 40% of the Company’s Class A Common Stock, par value $0.0001 per share (the “Common
Stock”), subject to the terms and conditions set forth therein; 
 WHEREAS, Sorrento Therapeutics, Inc. is entering into a First
Amendment to Subscription and Investment Agreement, dated of even date herewith (the “Sorrento Amendment”), with the Company, in connection with the purchase of $2,000,000 of the Company’s Common Stock, subject to the terms and
conditions set forth therein; 
 WHEREAS, the Company undertakes in Section 4.9 of the Subscription Agreement and Section 4 of the
Sorrento Amendment to take certain actions in respect of the nomination, appointment and election to its Board of Directors of one designee of Cambridge (the “Cambridge Designee”) and one designee of Sorrento (the “Sorrento
Designee”), respectively; 
 WHEREAS, in order to induce Cambridge to enter into the Subscription Agreement and to induce Sorrento to
enter into the Sorrento Amendment, the Stockholders wish to make provision to support the election of each of the Cambridge Designee and the Sorrento Designee to the Company’s Board of Directors following consummation of the transactions
contemplated by the Subscription Agreement; and 
 WHEREAS, the Closing (as defined in the Subscription Agreement) is conditioned upon the
Stockholders entering into this Agreement. 
 NOW, THEREFORE, in consideration of the mutual covenants and undertakings contained herein and
for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows: 

ARTICLE I 

DEFINITIONS 

SECTION 1.01. Definitions. As used in this Agreement, the following terms shall have the following meanings. Capitalized Terms
not otherwise defined herein shall the meaning ascribed to them in the Subscription Agreement. 

  
 2 








 ARTICLE II 

CORPORATE GOVERNANCE 

SECTION 2.01. Board of Directors; Voting of Shares.  

(a) Until the earlier of (a) the consummation of a firm-commitment initial public offering of the Common Stock approved by the
Company’s Board of Directors (an “IPO”), or (b) the date upon which Cambridge no longer has the right to nominate a Cambridge Designee under Section 4.9 of the Subscription Agreement, or relinquishes the right to designate a
Cambridge Designee (the earliest of such dates, the “Cut-Off Date”), each of the Stockholders, in any election of directors or at any meeting of the stockholders of the Company at which directors are to be elected, (i) will be present
(in person or by proxy) for purposes of establishing a quorum, and (ii) will vote, or grant a proxy to the Company or its authorized designee(s) to vote or act by written consent with respect to all shares of Common Stock Beneficially Owned by
such Stockholder (A) in favor of the Cambridge Designee for election to the Board of Directors and to serve as Co-Chairman, (B) in favor of the Sorrento Designee for election to the Board of Directors during such time as Sorrento has the
right to nominate a Sorrento Designee under Section 4 of the Sorrento Amendment, or relinquishes the right to designate a Sorrento Designee (the earliest of such dates, the “Sorrento Cut-Off Date”), and (C) each other director
nominee that is not a Cambridge Designee or Sorrento Designee (each a “Non-Investor Director”) recommended by at least a majority of the directors comprising the entire Board of Directors of the Company for election as directors of the
Company. 
 (b) Except as expressly provided above, each Stockholder shall be free to vote in his, her or its sole discretion all shares of
Common Stock Beneficially Owned by such Stockholder entitled to vote on any other matter submitted to or acted upon by stockholders of the Company; provided, however, that (i) Cambridge and its affiliates shall be subject to the
restrictions and limitations with respect to the shares of Common Stock Beneficially Owned by Cambridge set forth in the Subscription Agreement, and nothing in this Agreement shall be deemed to amend, alter, limit or curtail in any manner
whatsoever, the restrictions and limitations with respect to the shares of Common Stock Beneficially Owned by Cambridge set forth in the Subscription Agreement, including, without limitation, those restrictions and limitations set forth in Sections
4.10, 4.11 and 4.12. 
 SECTION 2.02. Removal; Filling of Vacancies. If requested by Cambridge or Sorrento in writing to the other
Stockholders prior to the Cut-Off Date or Sorrento Cut-Off Date, respectively, the Stockholders shall vote at regular or special meetings of stockholders and give written consent with respect to, such number of shares of Common Stock Beneficially
Owned by them as may be necessary to remove from the Board the Cambridge Designee or the Sorrento Designee, as the case may be. Any vacancy created by such removal shall be filled by party whose designee was so removed. The Cambridge
Designee may not be removed without the vote or written consent of Cambridge, and the Sorrento Designee may not be removed without the vote or written consent of Sorrento. In the event of the resignation, death or disqualification of the
Cambridge or Sorrento Designee, Cambridge or Sorrento, as the case may be, shall promptly nominate a new director, and each Stockholder shall promptly vote his, her or its shares of Common Stock Beneficially Owned to elect such replacement nominee
to the Board. 

  
 3 








 ARTICLE III 

MISCELLANEOUS 
 SECTION
3.01. Term, Notices.  
 (a) Unless terminated by mutual written agreement of the parties hereto, this Agreement shall be
effective from the date hereof until the expiration of the later to occur of the Cut-Off Date and the Sorrento Cut-Off Date. Notwithstanding the foregoing, the covenants, agreements and obligations of the parties with respect to the Cambridge
Designee shall automatically terminate on the Cut-Off Date, and the covenants, agreements and obligations of the parties with respect to the Sorrento Designee shall automatically terminate on the Sorrento Cut-Off Date. 

(b) All notices, requests, permissions, waivers and other communications hereunder shall be in writing and shall be deemed to have been duly
given (a) five (5) Business Days following sending by registered or certified mail, postage prepaid, (b) when sent, if sent by facsimile; provided that the facsimile transmission is promptly confirmed by telephone, (c) when
delivered, if delivered personally to the intended recipient and (d) one (1) business day following sending by overnight delivery via a national or international courier service and, in each case, addressed to a party at the following
address for such party: 
 If to any Stockholder other than Cambridge, to it at the following address: 

[Name of Stockholder]  

c/o Conkwest, Inc. 
 2533 South
Coast Highway 101, Suite 210 
 Cardiff by the Sea, CA 92007 

Fax: 858-380-1999 
 Attention:
Richard Gomberg, Secretary 
 with a copy to the Company at the above address; and 

with a copy to: 
 Greenberg
Traurig, LLP 
 The MetLife Building 

200 Park Avenue 
 New York, NY
10166 
 Telephone: (212) 801-9200 (phone) 

Facsimile: (212) 801-6400 (facsimile) 

Attention: Anthony J. Marsico, Esq. 

If to Cambridge, to it at the following address: 

  
 4 








 Cambridge Equities, LP 

9922 Jefferson Boulevard 
 Culver
City, CA 90232 
 Facsimile: (310) 405-7588 

Attention: Manager 
 If to
Sorrento, to it at the following address: 
 Sorrento Therapeutics, Inc. 

6042 Cornerstone Ct. West, Suite B 

San Diego, CA 92121 
 Telephone:
(858) 210-3701 
 Facsimile: (858) 210-3759 

Attention: Company Secretary 

SECTION 3.02. Applicable Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement
shall be governed by and construed and enforced in accordance with the internal laws of the State of California, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the
interpretations, enforcement and defense of the transactions contemplated by this Agreement (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be
commenced exclusively in the state and federal courts sitting in the City of Los Angeles, State of California. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of Los Angeles,
State of California for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of this Agreement), and hereby irrevocably waives,
and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each
party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to
such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any
right to serve process in any other manner permitted by law. 
 SECTION 3.03. Integration. This Agreement, the Subscription
Agreement, and the Registration Rights Agreement, dated of even date between the Company and Cambridge, contain the entire understanding of the Company and Cambridge with respect to the subject matter hereof, and supersede all prior agreements and
understandings between such parties with respect to the subject matter hereof. This Agreement and the Sorrento Amendment contain the entire understanding of the Company and Sorrento with respect to the subject matter hereof, and supersede all prior
agreements and understandings between such parties with respect to the subject matter hereof. 

  
 5 








 SECTION 3.04. Descriptive Headings. The headings in this Agreement are for
convenience of reference only and shall not limit or otherwise affect the meaning of terms contained herein. 
 SECTION 3.05.
Severability. The invalidity or unenforceability of any provisions of this Agreement in any jurisdiction shall not affect the validity, legality or enforceability of the remainder of this Agreement in such jurisdiction or the validity,
legality or enforceability of this Agreement, or any provision hereof, in any other jurisdiction, it being intended that all rights and obligations of the parties hereunder shall be enforceable to the fullest extent permitted by law. 

SECTION 3.06. Successors, Assigns, Transferees. The provisions of this Agreement shall be binding upon and inure to the benefit
of the parties hereto and their respective heirs, successors and permitted assigns. Neither this Agreement nor any right, remedy, obligation or liability arising hereunder or by reason hereof may be assigned by any party without the prior written
consent of the other parties hereto. Any purported assignment of rights under this Agreement in violation of this Section 3.06 shall be void and of no effect. 

SECTION 3.07. Amendments; Waivers. No provision of this Agreement may be waived, modified, supplemented or amended except in a written
instrument signed, in the case of an amendment, each of the parties hereto or, in the case of a waiver, by the party against whom enforcement of any such waived provision is sought. No waiver of any default with respect to any provision, condition
or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to
exercise any right hereunder in any manner impair the exercise of any such right. 
 SECTION 3.08. Counterparts. This
Agreement may be executed in two or more counterparts, each of which shall be deemed an original but all of which, when taken together, shall constitute one and the same Agreement. 

SECTION 3.09. Specific Performance. Each of the parties hereto acknowledges and agrees that in the event of any breach of this
Agreement, the non-breaching parties would be irreparably harmed and could not be made whole by monetary damages. The parties hereto, in addition to any other remedy to which they may be entitled at law or in equity, shall be entitled to seek an
injunction or injunctions to prevent breaches of the provisions of this Agreement and to enforce specifically the terms and provisions hereof without the necessity of securing or posting any bond or providing prior notice. 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 6 








 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written. 

 

			
	CONKWEST, INC.
		
	By:	 	  

	Name:	 	Barry Simon
	Title:	 	President and CEO


 
			
	
	SORRENTO THERAPEUTICS, INC.
		
	By:	 	  

	Name:	 	Henry Ji
	Title:	 	President and CEO


 
			
	 No. of Class A Common Shares as of

the date hereof:                    

	
	CAMBRIDGE EQUITIES, LP
		
	By:	 	  

	Name:	 	
	Title:	 	


 
			
	 No. of Class A Common Shares as of

the date hereof:                     

	
	  

	STEVE GORLIN
	 No. of Class B Common Shares as of

the date hereof:*                     




  
 7 








 
	
	
	  

	BARRY SIMON
	 No. of Class B Common Shares as of

the date hereof:*
                    

	
	  

	HANS KLINGEMANN
	 No. of Class B Common Shares as of

the date hereof:*
                    



  

	*	Class B Common Shares shall be reclassified into an equal number of Class A Common Shares. 


  
 8 








 SCHEDULE A 

STEVEN GORLIN 
 BARRY SIMON 

HANS KLINGEMANN 

  
 9